November 10th, 2026Allergy Rounds With Dr. AutumnAutumn Burnette, MD, hosts a new monthly allergy and immunology podcast from HCPLive, opening with an episode on hereditary angioedema.Read more
November 9th, 2026The HCPFive: Top News for Healthcare Providers from the Week of 11/1Stay updated with the latest healthcare breakthroughs, including 96-week durability data for GSK’s bepirovirsen in hepatitis B, and more.Read more
November 9th, 2026Skin of Color Savvy: Trials & Trust—What Meaningful Representation MeansMona Shahriari, MD, and Valerie D. Callender, MD, discuss trial diversity, better outcome measures, and how investigators can earn patient trust.Read more
November 8th, 2026SHASTA-3/4: Plozasiran Could Cut Acute Pancreatitis Risk by 78% Across sHTG SpectrumIn 757 adults with severe hypertriglyceridemia, plozasiran cut acute pancreatitis events by 78% overall and 91% in those with recent prior pancreatitis.Read more
November 7th, 2026GLP-1 RAs Linked to Lower Diabetes, CV Risk than Metformin in PrediabetesCompared to metformin, GLP-1 RAs were linked to more normoglycemia reversion and less diabetes progression in 256,492 adults with prediabetes.Read more
November 10th, 2026Don't Miss a Beat: What Lp(a)HORIZON and ZEUS Teach About Clinical Trial ScienceLp(a)HORIZON and ZEUS hit their biomarker targets but not MACE. Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, unpack both at AHA 2026.Read more
November 10th, 2026Rezpegaldesleukin's Early Treg Signal in AD: Emma Guttman-Yassky, MDEmma Guttman-Yassky, MD, discusses biomarker data showing rezpegaldesleukin's regulatory T-cell mechanism separates from placebo early.Read more
November 10th, 2026OptIMMize-1: Risankizumab Clears Skin in Children, Teens with PsoriasisRisankizumab improved skin clearance, itch, and quality of life through 52 weeks in pediatric psoriasis in the phase 3 OptIMMize-1 study.Read more